L.Ronzonietal
treatmentofadultpatientswithmoderateorsevereSCD(Platt,2008).EventhoughHCamelioratesacutecomplica-tionsandprolongslifeexpectancyinsomepatientswithSCD,manypatientsfailtoachieveclinicallysigni cantincreasesofHbF(Steinbergetal,2003;Bakanayetal,2005).Moreover,todate,theseHbFinducershaveshownonlymoderateresponseinamajorityofb-thalassaemiapatients,mostofwhomcontinuetosufferfromprofoundanaemia(Testa,2009;Atweh&Fathallah,2010).NewHbF-inducingagentsthatcouldovercomethelimitationofexistingdrugs(cytotoxicity,inhibitionoferythroiddifferentiationandmutagenicity;Perrine,2005)arecurrentlyunderinvestigation(Perrineetal,2010;Higgsetal,2012;Musallametal,2013).Amongthesecompounds,theHDACinhibitorshaveaninhibitoryactivityonhistonedeacetylases,leadingtohyper-acetylationofe-aminogroupsoflysineresiduesinhistones.HDACinhibitioncausesadecreasedassociationofbasiccorehistoneproteinswiththeDNA,renderingcertaingenesmoreaccessibletothetranscriptionalmachinery(Caoetal,2004).Givinostat(GVS,ITF2357)isarecentlyidenti edHDACinhibitorofthehydroxamatefamily,whichinhibitsbothclassIandclassIIHDAC(Leonietal,2005).GVShasanti-proliferativeandproapoptoticactivityagainstseveralcancercells,includingacutemyeloidleukemia(AML)andmultiplemyeloma(MM)cellsinvitroandinvivo(Golayetal,2007).Indeed,ithasenteredphaseIIclinicaltrialsforthetreatmentofMM,AML,HodgkinlymphomaandJAK2V617F-positivemyeloproliferativeneoplasms(Calzadaetal,2012).Ontheotherhand,atlowconcentrationsthatshownocytotoxiceffectsonnormalandtumourcells,GVSinhibitsthepro-ductionofpro-in ammatorycytokinessuchasinterleukin(IL)1,IL6,tumournecrosisfactor(TNF)-aandinterferon(IFN)-c.Thisdrug’sabilityhasledtoitbeingtestedinclini-caltrialsonin ammatorydiseasessuchasidiopathicarthritisandCrohndisease(Vojinovic&Damjanov,2011).LittleisknownabouttheactivityofGVSonHbFinduction.Inthisreport,weinvestigatedeffectsofGVSonerythropoiesisandHbsynthesisusingCD34+progenitorscellsfromnormalandSCDpatientsasaninvitroerythropoiesismodel.
ThedatapresentedshowthatGVSatlowconcentrationinducesHbsynthesiswithoutaffectingcellviabilityanddifferentiationbothinhealthyandSCDCD34+-derivederythrocytesbyregulatingthetranscriptionofHBG1/HBG2andHBB(c-andb-globingenes).Itsef cacyinHbinduc-tionissimilartohydroxycarbamide,suggestingthatGVSmayrepresentaninterestingnewtherapytobestudiedinpatientswithSCDandb-haemoglobinopathies.
MaterialsandmethodsDrugs
Givinostat(ITF2357;diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-ylmethyl]-ammoniumchloride;monohydrate;Italfarmaco,patentWO97/43251,2
US6034096)wassynthesizedbyItalfarmaco(Milan,Italy)anditspurityandidentitywerecon rmedbyhighperfor-manceliquidchromatographyandmassspectroscopy.Itwasdissolvedindimethylsulfoxide(DMSO, nalconcentration,0Á1%);allcontrolscontained0Á1%DMSO.HCandsodiumbutyrate(NaBut)werepurchasedfromSigma-Aldrich(Milan,Italy).
Erythroidcellcultures
Afterinformedconsenthadbeenobtained,peripheralblood(15–20ml)from vehealthyvolunteersand veSCDpatientswascollectedintosterileheparinizedtubes.AllSCDpatientswereadultswithnegativeclinicalhistoryforsicklecrisesandanypainduringtheprevious6months.Light-densitymononuclearcellswereobtainedbycentrifugationonaLymphoprep(NycomedPharma,Oslo,Norway)densitygradientandthenenrichedforCD34+cellsbypositiveselec-tionusingCD34+microbeads(MiltenyiBiotech,Auburn,CA,USA)accordingtothemanufacturers’instructions(CD34+cells:0.1%ofmononuclearcells;CD34+purityassessedby owcytometricanalysis:98%).CD34+cellswereculturedatadensityof105cells/mlinalpha-minimalessen-tialmedium(a-MEM;GIBCO,GrandIsland,NY,USA)sup-plementedwith30%fetalbovineserum(FBS;GIBCO),aspreviouslydescribed(Ronzonietal,2008).Brie y,toinducecelldifferentiationanderythroidmaturation,cellswereculturedwith20ng/mlrecombinanthuman(rH)stemcellfactor(SCF;PeproTech,London,UK),10ng/mlrHinterleu-kin-3(IL3;PeproTech)and3u/mlrHerythropoietin(rHu-epo;Janssen-Cilag,Milan,Italy).Cellswereincubatedat37°Cinanatmosphereof5%CO2for14d;after7dofcul-turethemediumwaschangedtoensuregoodcellfeeding.GVS,HCandNaButwereaddedatdifferentconcentrationsatdays0ofcultureandre-addedevery2d.
Cellmorphologyanalysis
Cellmorphologywasanalysedonday14ofculturebylightmicroscopyoncytocentrifuged(ShandonAstmoor,Runcorn,UK)smearsstainedwithMay-Grunwald–Giemsa,byassess-ingandcountingcellsin vedifferent eldsofview,foratotalof500–600cells.Haemoglobin-containingcellswereidenti edbybenzidinestaining.
Flowcytometry:phenotypiccharacterizationofthecells
Atday14ofculture,theexpressionofcell-surfaceantigenswasanalysedby owcytometry.Cells(105)were rstincu-batedinaphosphate-bufferedsaline(PBS;GIBCO)solutionwith0Á1%sodiumazide(NaN3;CarloErba,Milan,Italy),4%NewbornCalfSerum(Sigma-Aldrich)and4%MouseSerum(Sigma-Aldrich)toblockFcreceptorsandavoidnon-speci cantibodybinding.Cellswerethenlabelledwith uoresceinisothiocyanate(FITC)-conjugateanti-CD71and
ª2014JohnWiley&SonsLtd,BritishJournalofHaematology
2014 TO P Modulation o... 暂无评价 8页 免费...Histone deacetylase inhibitors are potent inducers ...Regulation of gene expression occurs also via ...
Leukemia Stem Cells by Histone Deacetylase...modulation of the acetylation status of nonhistone ...We also observed reduced expression of genes with...
Histone deacetylase inhibitor (HDI) treatment upregulates the expression of the...to HDI treatment, although the particular genes that are up- and ...
Histone deacetylase inhibitor prevents cell growth ... 318 genes were deregulated: 250 genes were ...to access global gene expression modulation upon ...
Synergy of DNA methylation and histone deacetylase inhibitors in the re-expression of RASSFIA an_专业资料。Snryo yeg fDNA ehai dhitedaeyls mtyltonan son ...
Synergy of DNA methylation and histone deacetylase inhibitors in the re-expression of RASSFIA an_专业资料。Snryo yeg fDNA ehai dhitedaeyls mtyltonan son ...
热门文档